DK3016977T3 - Humane anti-il-32-antistoffer - Google Patents

Humane anti-il-32-antistoffer Download PDF

Info

Publication number
DK3016977T3
DK3016977T3 DK14735565.5T DK14735565T DK3016977T3 DK 3016977 T3 DK3016977 T3 DK 3016977T3 DK 14735565 T DK14735565 T DK 14735565T DK 3016977 T3 DK3016977 T3 DK 3016977T3
Authority
DK
Denmark
Prior art keywords
antistoffer
humane
humane anti
Prior art date
Application number
DK14735565.5T
Other languages
English (en)
Inventor
Adrian Hayday
Kai Krohn
Annalisa Macagno
Pärt Peterson
Mike Rothe
Martin Woodward
Syeda F Y Haque
Kai Kisand
Shimobi Onuoha
Original Assignee
Immunoqure Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunoqure Ag filed Critical Immunoqure Ag
Application granted granted Critical
Publication of DK3016977T3 publication Critical patent/DK3016977T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK14735565.5T 2013-07-03 2014-07-03 Humane anti-il-32-antistoffer DK3016977T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13174937 2013-07-03
PCT/EP2014/064163 WO2015001010A1 (en) 2013-07-03 2014-07-03 Human anti-il-32 antibodies

Publications (1)

Publication Number Publication Date
DK3016977T3 true DK3016977T3 (en) 2020-01-27

Family

ID=48703305

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14735565.5T DK3016977T3 (en) 2013-07-03 2014-07-03 Humane anti-il-32-antistoffer

Country Status (15)

Country Link
US (2) US10081676B2 (da)
EP (1) EP3016977B1 (da)
JP (1) JP6486914B2 (da)
KR (1) KR102231685B1 (da)
CN (2) CN105518024B (da)
AU (1) AU2014286128B2 (da)
CA (1) CA2916895C (da)
DK (1) DK3016977T3 (da)
ES (1) ES2768335T3 (da)
HK (1) HK1219962A1 (da)
HR (1) HRP20200058T1 (da)
PL (1) PL3016977T3 (da)
PT (1) PT3016977T (da)
SI (1) SI3016977T1 (da)
WO (1) WO2015001010A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3016977B1 (en) 2013-07-03 2019-10-23 ImmunoQure AG Human anti-il-32 antibodies
WO2020146393A1 (en) 2019-01-07 2020-07-16 Shattuck Labs. Inc. Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
WO2023200256A1 (ko) * 2022-04-15 2023-10-19 건국대학교 산학협력단 Il-32쎄타 뮤턴트를 포함하는 조성물 내지 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
WO2005047478A2 (en) * 2003-11-12 2005-05-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for regulation of tumor necrosis factor-alpha
IL169622A0 (en) * 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
KR100855299B1 (ko) * 2007-02-16 2008-08-29 건국대학교 산학협력단 인간 il-32 특이 항원결정기를 갖는 단일클론항체,특이항체분비 융합 세포주 및 항체들을 이용한 il-32측정법
US20090263377A1 (en) * 2008-04-10 2009-10-22 Charles Lin Il-32b-targeted diagnosis and therapy
JP2011072248A (ja) * 2009-09-30 2011-04-14 Evec Inc 狂犬病ウイルスに対するヒト抗体ならびにその組成物
CN101703762A (zh) * 2009-11-03 2010-05-12 武汉大学 一种人白介素-32在治疗或预防a型流感病毒感染药物中的应用
KR101072895B1 (ko) * 2009-12-24 2011-10-17 주식회사 녹십자 B형 간염 바이러스 표면 항원에 특이적으로 결합하는 인간 항체
EP2538964A4 (en) * 2010-02-25 2013-07-31 Univ Manitoba MODULATION OF CYTOKININDUCED CHRONIC INFLAMMATORY REACTIONS
SI2797952T1 (sl) * 2011-12-28 2019-07-31 Immunoqure Ag Postopek za pripravo monoklonskih avto-protiteles z želeno specifičnostjo
EP3016977B1 (en) 2013-07-03 2019-10-23 ImmunoQure AG Human anti-il-32 antibodies

Also Published As

Publication number Publication date
PL3016977T3 (pl) 2020-06-29
KR20160028465A (ko) 2016-03-11
CN110724193B (zh) 2023-05-05
CA2916895C (en) 2022-08-09
US20160368981A1 (en) 2016-12-22
KR102231685B1 (ko) 2021-03-26
CN105518024B (zh) 2019-12-06
HK1219962A1 (zh) 2017-04-21
AU2014286128B2 (en) 2019-10-10
PT3016977T (pt) 2020-01-30
JP6486914B2 (ja) 2019-03-20
US20190112367A1 (en) 2019-04-18
US10081676B2 (en) 2018-09-25
WO2015001010A1 (en) 2015-01-08
EP3016977B1 (en) 2019-10-23
ES2768335T3 (es) 2020-06-22
AU2014286128A1 (en) 2016-01-28
EP3016977A1 (en) 2016-05-11
CN110724193A (zh) 2020-01-24
CN105518024A (zh) 2016-04-20
CA2916895A1 (en) 2015-01-08
JP2016529881A (ja) 2016-09-29
HRP20200058T1 (hr) 2020-04-03
SI3016977T1 (sl) 2020-03-31
US10975144B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
DK3689865T3 (en) Hidtil ukendte aminopyrimidinderivater
DK3088517T3 (en) Humant anti-il-33-neutraliserende monoklonalt antistof
DK3736291T3 (en) Anti-FCRH5-antistoffer
DK3354246T3 (en) Udstyrsmonteringssystem
DK3077519T3 (en) Cmv-vacciner
EP3041350A4 (en) IMPROVED BAIT
EP2957205A4 (en) HAND DRYER
ZA201600743B (en) Decoy
DK3470074T3 (en) Probiotika
DK3016978T3 (en) Humane anti-ifn-alpha-antistoffer
EP2970310A4 (en) 5-Bromo-indirubins
AU353576S (en) Stamphousing
EP2853297A4 (en) kendama
DK3016977T3 (en) Humane anti-il-32-antistoffer
DK3056208T3 (en) Immunpotentiator
DK2979701T3 (en) Antitumormiddel indbefattende irinotecanhydrochloridhydrat
GB201301924D0 (en) Pest bait-station
DK2989854T3 (en) Strømstyret opvarmningssystem
AU4899P (en) Herbie53 Iresine herbstii
AU4953P (en) Flogazora Gazania rigens
AU4977P (en) Harrosy Gaura lindheimeri
AU356313S (en) Bibbed lure
AU356315S (en) Lure
GB201417087D0 (en) No detials
AU353330S (en) Kettlebell